Citations

Clear

381 citation(s) found for "Gross, MS".

Impact of Calvarial Burring in Squamous Cell Carcinoma of the Scalp Without Gross Calvarial Involvement
Baratz, Hannah , Schmidtman, Daniel C. , Moore, E.J., Tasche, K., Abel, Kathryn M. Van , Baratz, Hannah Q , Yin, Linda X , Tasche, Kendall K. , Van Abel, Kathryn M , Schmidtman, Daniel C , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | February 28, 2026 | Volume: 135 | Issue: 7 | Pages: 530-534

10.1177/00034894261419886 | PMID 41761567 Get It

Background: To compare oncologic and postoperative outcomes in patients with scalp squamous cell carcinoma with periosteal, but not gross calvarial, involvement, treated with margin-clearing excision including either calvarial burring or periosteal excision alone. Study Design: Retrospective cohort study. Setting: Single tertiary academic referral center. Methods: We retrospectively reviewed surgical cases from January 2001 to January 2025. Inclusion criteria: patients ≥18 years with biopsy-proven scalp squamous cell carcinoma involving the periosteum without cortical invasion on imaging. Management of the deep margin included either burring of the outer table or periosteal excision alone. Demographic, surgical, and oncologic outcomes were collected and analyzed descriptively. Results: Twenty patients met inclusion criteria. Median age was 70 (range 56-92), and 18 (86%) were male. Thirteen (65%) patients underwent calvarial burring, 7 (35%) underwent periosteal excision. Local recurrence occurred in 31% and 29% of the burring group and non-burring group. Disease-free survival at 2 years was 46% and 57% in the burring and non-burring group, respectively. Overall survival at 2 years was 77% and 86% in the burring and non-burring group. Three patients in the burring group had local recurrences with intracranial extension, 1 died of disease, 1 died with disease and concurrent meningitis, 1 is alive with disease recurrence currently on palliative treatment. There were 7 disease-related deaths. Conclusion: Burring did not confer a significant oncologic advantage compared to periosteal excision alone when there was no gross cortical invasion. Local recurrence in patients undergoing calvarial burring was associated with intracranial extension of disease.
Artificial Intelligence for Gastroenterology Practice: A Modified Delphi Consensus
Gross, Seth, Shaukat, Aasma, Afzali, A, Ahn, Joseph C., Bajaj, Jasmohan S. , Barkin, Jodie A. , Bilal, Mohammad, Chawla, Saurabh , Coelho-Prabhu, Nayantara, Enslin, Sarah , Feld, Andrew, Gagneja, Harish K., Hass, David J., Horst, Sara N., Jones, Patricia D. , Kushnir, Vladimir M., Leggett, Cadman L. , Leung, Galen G., Mascarenhas, M., Parasa, Sravanthi, Parsa, Nasim , Schairer, Jason N., Spiegel, Brennan, Suthrum, Praveen, Thomas, Sapna, Phillips, Meridith E., Coelho–Prabhu, Nayantara , Spiegel, Brennan , Afzali, Anita , Ahn, Joseph , Bilal, Mohammad , Afzali, Anita , Ahn, Joseph C , Coelho-Prabhu, Nayantara , Enslin, Sarah M , Hernandez-Barco, Yasmin G , Horst, Sara , Jacobson, Brian C , Jones, Patricia D , Kaul, Vivek , Leggett, Cadman L , Leung, Galen , Mascarenhas, Miguel , Parasa, Sravanthi , Shah, Eric D , Simonetto, Douglas A , Stidham, Ryan W , Suthrum, Praveen , Thomas, Sapna , Phillips, Meridith E , Bilal, Mohammad , Spiegel, Brennan , Shaukat, Aasma , Afzali, Arya , Feld, Andrew D., Hernandez‐Barco, Yasmin G. , Horst, Sara , Kushnir, Vladimir , Parasa, Sravanthi , Schairer, Jason, Shah, Eric D. , Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | February 10, 2026 | Volume: 121 | Issue: 4 | Pages: 1017-1024

10.14309/ajg.0000000000003944 | PMID 41665234 Get It

INTRODUCTION: The American College of Gastroenterology assembled a multidisciplinary task force to evaluate the current state and future direction of artificial intelligence (AI) in gastroenterology, hepatology, and endoscopy leading to the development of consensus-based recommendations for responsible AI integration in clinical practice. METHODS: A total of 32 subject-matter experts and 12 industry partners, representing diverse practice settings and expertise, conducted subgroup literature reviews across 5 key areas (endoscopy, practice management clinical applications, training and education, inflammatory bowel disease and liver disease, ethics and equity). Draft statements were developed and rated on a 5-point Likert scale using a modified Delphi process. A consensus was set at ≥70% combined agreement. Nonconsensus items were revised and revoted electronically. RESULTS: A total of 43 statements, 40 (93%) reached consensus in round 1 and the remaining 3 achieved consensus after round 2. Evidence supports computer-aided detection improving adenoma detection rate and miss rate in controlled studies, with mixed real-world impact and insufficient long-term outcomes (e.g., interval colon cancer rate). Recommendations emphasize thorough validation and reduction of bias by heterogeneous Data sets. Outside endoscopy, ambient AI scribes, natural language processing (NLP)-enabled coding, workflow optimization, and previous authorization support show potential. Training recommendations endorse a structured AI curriculum while preserving independent procedural competence to avoid deskilling. In inflammatory bowel disease and hepatology, AI could help improve diagnostic accuracy, help predict risk of disease progression, and help guide therapy. Equity, governance, and reimbursement statements call for chain-of-custody data protections, specialty-society oversight, and payment models that reward quality and cost reduction. DISCUSSION: This consensus outlines how AI can augment rather than replace clinical expertise while promoting safety, transparency, interoperability, and equity. Priorities include pragmatic and prospective trials, multi-institutional data-sharing consortia, bias mitigation, and workforce training to enable trustworthy and clinically impactful AI adoption in gastroenterology, liver, and endoscopy care.
Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States
Leapman, Michael S., Long, Jessica B., Westvold, Sarah , Rabil, Maximilian , Sprenkle, Preston C. , Kim, Isaac Y., Spilberg, Gabriela , Saperstein, Lawrence, Fallah, Jaleh , Suzman, Daniel L. , Lerro, Catherine, Xu, Jianjin , Rivera, Donna R. , Karnes, R. Jeffrey, Dinan, Michaela, Mitchell, Aaron Philip , Wang, S, Gross, Cary P. , Leapman, Michael , Westvold, Sarah J. , Leapman, Michael S , Dinan, Michaela A , Mitchell, Aaron P , Wang, Shi-Yi , Ma, Xiaomei , Rivera, Donna R. , Kluetz, Paul Gustav , Karnes, R. Jeffrey , Dinan, Michaela A. , Kunst, Natalia , Ma, Xiaomei

Mayo Clinic

JCO Oncology Practice | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-25-00617 | PMID 41632928 Get It

PURPOSE Despite evidence of diagnostic accuracy but unclear long-term clinical benefit, national utilization patterns of prostate-specific membrane antigen positron emission tomography (PSMA-PET) are undefined. METHODS We conducted a serial cross-sectional study to evaluate the use of PET imaging among commercial insurance beneficiaries with prostate cancer using administrative claims from deidentified Blue Cross Blue Shield Axis database. Eligible patients included prevalent and incident prostate cancer cases. We calculated the proportions undergoing PET imaging in semiannual periods from January 1, 2016, through December 31, 2024. We examined the association between regional-level contextual sociodemographic and health care characteristics, and regional use of PSMA-PET imaging in 2024. RESULTS A total of 514,750 male beneficiaries age 40-89 years with prostate cancer were identified between 2016 and 2024. The proportion of individuals with prostate cancer undergoing PET imaging increased from 4.5 [95% CI, 4.1 to 4.9] per 1,000 in the first half of 2016 to 77.6 (95% CI, 76.2 to 79.1) per 1,000 in the second half of 2024, P < .001. Increases in PET were driven by uptake of PSMA-PET following approval in 2021, which increased from 0.8 (95% CI, 0.6 to 0.9) per 1,000 in the second half of 2021 to 77.0 (95% CI, 75.5 to 78.5) per 1,000 in the second half of 2024, P < .001. PSMA-PET use in 2024 was higher in regions with greater education (99.3 v 114.6 per 1,000 in lowest [Q1] v highest [Q4] educated) and income (95.4 v 112.3 per 1,000 in Q1 v Q4 income) measures, P < .001. CONCLUSION PSMA-PET was rapidly incorporated into clinical practice among commercial insurance beneficiaries with prostate cancer with higher adoption in geographic regions with higher income and education.
A Phosphorylation Switch Governs KIF11’s Mechanical Output During Mitosis
Šemić, Amila , Reddy, Babu Jn, Muretta, Joseph M. , Vandal, Sarah E. , Thompson, Alex F. , Fonseca, Cindy L., Rosenfeld, Steven S. , Gross, Steven P. , Stumpff, Jason , Reddy, Babu J.N.

Mayo Clinic

No container title available | January 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.23.700875 | PMID 41648279 Get It

Abstract The kinesin-5 motor protein KIF11 is crucial for mitotic spindle assembly, driving the separation of spindle poles through microtubule sliding. Src-family kinases phosphorylate KIF11 at multiple tyrosine residues within its motor domain, but the mechanistic consequences of these modifications remain unclear. Here, we dissect the role of phosphorylation at Y211 using phospho-mimetic (Y211E) and non-phosphorylatable mutants (Y211F) in biochemical, biophysical, and cellular assays. Optical trapping and Förster resonance energy transfer (FRET) analyses reveal that Y211 phosphorylation slows neck-linker docking, reducing motor velocity and force generation under load. In human cells, Y211E expression impairs bipolar spindle formation and decreases spindle pole separation velocity, while Y211F shortens steady-state spindle length. Fluorescence recovery after photobleaching (FRAP) analyses show that Y211E accelerates motor turnover on spindle microtubules, consistent with the mutant motor’s heightened load sensitivity. Together, these findings support a model in which Src-mediated phosphorylation at Y211 acts as a rheostat to tune KIF11 mechanochemistry and spindle assembly dynamics, linking cancer-relevant kinase signaling to mitotic force generation.
Evoked connectivity of cortical stimulation for memory
Cole, Eric R. , DeHaan, Riley D. , Blanpain, Lou T, Sakon, John J. , Sheth, Sameer, Sperling, Michael, Lega, Bradley, Worrell, Greg, Kahana, Michael J. , Blanpain, Lou T. , Laxpati, Nealen G. , Sheth, Sameer A. , Zaghloul, Kareem A. , Jobst, Barbara C. , Sperling, Michael R. , Lega, Bradley Charles , Worrell, Gregory A. , Gross, Robert E.

Mayo Clinic

No container title available | January 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.10.26343861 Get It

Abstract Despite promising results, it remains unclear how to optimally target and personalize closed-loop stimulation to ameliorate deficits in memory and other cognitive functions. We hypothesized that evoked connectivity – the measurement of neural pathway activation using single pulses of electrical stimulation – can guide patient-specific selection of stimulation location and parameters for memory. We characterized brain-wide evoked connectivity profiles of stimulation in memory-related brain regions recorded from 81 patients undergoing intracranial monitoring for epilepsy, showing that greater evoked connectivity between the lateral temporal cortex and the broader memory network (including the mesial temporal lobe, limbic regions and prefrontal cortex) corroborates observations of memory improvement by lateral temporal cortex stimulation. We first found that the lateral temporal cortex, compared to other stimulated regions, evokes the greatest and most distributed connectivity response throughout other memory-related regions. Evoked connectivity in downstream regions is greatest when stimulating a previously identified optimal target for memory improvement, bordering white matter at the rostrocaudal center of the middle temporal gyrus. Evoked connectivity corroborates other biomarkers of memory improvement by closed-loop stimulation, including increased resting-state functional connectivity between stimulated and recorded sites and increased modulation of oscillatory power. These results provide insight into the network mechanisms of stimulation for memory and suggest that evoked connectivity can more broadly predict the functional effects of closed-loop stimulation to prospectively guide targeting and parameter selection.
Implementation of the REFLECT Communication Curriculum for Clinical Oncology Graduate Medical Education
Vern-Gross, T.Z., Laughlin, Brady, Kough, Katherine, Rule, William G., Patel, Samir H. , Ashman, Jonathan B. , Vern-Gross, Tamara Z, Laughlin, Brady S. , Langley, Natalie, Ernst, Brenda , Langley, Natalie R.

Mayo Clinic

Journal of Palliative Medicine | January 12, 2026 | Volume: 27 | Issue: 2 | Pages: 231-235

10.1089/jpm.2023.0316 | PMID 38301158 Get It

Living liver donor safety: Preoperative aspects of living liver donation—Guidelines from the ILTS–iLDLT consensus conference
Patel, Madhukar , Magistri, P., Sayed, Blayne A. , Rammohan, Ashwin, Humar, Abhinav, Abbey, Susan , Badenoch, Heather, Bhangui, Pooja , Cattral, M C, Durand, F., Hibi, Taizo, Jhaveri, Kartik , Kabacam, Gokhan, Khan, Maaz , Malik, Ashish, Nadalin, S., Ng, Vicky L, Petrowsky, Henrik , Pillai, Anjana , TOKAT, YAMAN, Wong, Tiffany, Yilmaz, Sezai, Yoshizumi, T., Nl, Ascher, Broering, Dieter, Burra, Patrizia, Chen, Chao-Long, Lerut, J., Mas, Valeria R. , Taner, Timucin, Terrault, Norah, Vyas, Mary, Wiggins, Chantal, Heimbach, Julie, Ng, Vicky L. , Rela, M., Patel, Madhukar S. , Selzner, Nazia , Sayed, Blayne A , Rammohan, Ashwin , Humar, Abhinav , Abbey, Susan , Ng, Vicky L , Rela, Mohamed , Bhangui, Prashant , Selzner, Nazia , Khan, Mohammad Qasim , Magistri, Paolo , Humar, Abhinav , Cattral, Mark S. , Durand, François , Gross, Jed Adam , Hibi, Taizo , Kabaçam, Gökhan , Malik, Ashish , Nadalin, S., Reddy, Mettu Srinivas , Wong, Tiffany, Yilmaz, Sezai , Yoshizumi, Tomoharu , Bröering, Dieter C. , Burra, Patrizia , Hirschfield, Gideon M. , Taner, Timuçin , Terrault, Norah A. , Heimbach, Julie K. , Rela, Mohamed , Bhangui, Prashant

Mayo Clinic

Liver Transplantation | January 9, 2026 | Volume: 32 | Issue: 7 | Pages: 1049-1065

10.1097/lvt.0000000000000798 | PMID 41511461 Get It

Living donor liver transplantation (LDLT) is an established therapy with curative intent for pediatric and adult patients with acute liver failure and end-stage liver disease. Donor safety remains paramount and commences during preoperative evaluation and assessment. Given the importance of the topic, the International Liver Transplantation Society and International Living Donor Liver Transplantation Group consensus conference on Living Liver Donor Safety was convened in March 2025 (Toronto, Canada). Recommendations were based on the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for assessment of recommendations, and the Danish model of consensus was followed. This report presents 28 recommendations from the working group focused on addressing clinically relevant questions related to the preoperative aspects of living donor safety including assessment of donor acceptability (age, body mass index and hepatic steatosis; medical conditions and contraindications), medical and surgical workup (liver function and procoagulant workup; anatomical considerations and safe remnant), and psychosocial evaluation (timing and team; underlying conditions; non-directed, paired, and anonymous directed donors; urgent living donor workups for acute liver failure).
SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)
Kim, Aerang, Ballman, K., Wolters, Pamela L. , Heise, Rachel S. , Shern, J., Sundby, R. Taylor , Lindenberg, Liza , Lee, Min-Jung , Rastogi, Shraddha , Shahsavari, Shirin, Tine, Brian A. Van, Meyer, Christian F. , Pratilas, Christine A. , Collins, Natalie B. , Coyne, Geraldine O'Sullivan, Chen, Alice P. , Dombi, Eva, Shrestha, Roshan L., Cichowski, Karen M. , Widemann, B. C., Ballman, Karla V. , Kim, AeRang , Cichowski, Karen , Shern, Jack F. , Sundby, R. Taylor , Kim, AeRang , Ballman, Karla , Shern, Jack F , Sato, Nahoko , Shahsavari, Shirin , Hirbe, Angela C , Van Tine, Brian A , Meyer, Christian , Pratilas, Christine A , Collins, Natalie B , O'Sullivan Coyne, Geraldine , Chen, Alice P , Dombi, Eva , Shrestha, Roshan L , Gross, Andrea M , Reinke, Denise , Widemann, Brigitte C , Heise, Rachel , Wolters, Pamela L. , Hirbe, Angela C. , Tine, Brian A. Van , Dombi, Eva , Gross, Andrea M. , Reinke, Denise K.

Mayo Clinic

Clinical Cancer Research | January 8, 2026 | Volume: 32 | Issue: 6 | Pages: 1068-1077

10.1158/1078-0432.ccr-25-2887 | PMID 41504652 Get It

Abstract Purpose: Combined mTOR and MEK inhibition, critical components of the RAS effector pathway underlying the pathogenesis of neurofibromatosis type 1 (NF1)–related tumors, caused regression in a malignant peripheral nerve sheath tumor (MPNST) transgenic mouse model. The primary objective was to determine the clinical benefit rate in patients with unresectable/metastatic MPNST. Patients and Methods: The study design was a multi-institutional, open-label, Simon two-stage, phase II study of the MEK inhibitor selumetinib and mTOR inhibitor sirolimus. Patients ≥12 years with histologically confirmed MPNST received selumetinib 50 mg twice daily and sirolimus 4 mg once daily, in continuous 28-day cycles. Correlative studies evaluated patient-reported pain, immune signature in peripheral blood, and cell-free DNA (cfDNA). Results: A total of 21 heavily pretreated patients [seven females; median age, 41 years (range, 16–72); and 14 with NF1] with advanced disease enrolled at five participating sites. Clinical benefit was observed in only one of seven in stage 1 and one of 14 patients in stage 2. The median number of cycles was two (range, 1–6). Most common adverse events (AE) were grade ≤2 gastrointestinal toxicity, acneiform rash, hypertriglyceridemia, mucositis, and transaminase elevation. Unlike the preclinical model, early 18F-fluorodeoxyglucose PET scan performed during cycle 1 demonstrated partial metabolic responses in five patients (24%), but these did not correlate with objective responses after cycle 2. cfDNA was able to detect MPNST with the potential to be a biomarker of response. Conclusions: The combination was safe, with manageable and expected AEs, but did not meet study parameters for further evaluation in MPNST. Correlative studies were informative and may guide future therapeutic trials of MPNST.
Cognitive heterogeneity of data‐driven phenotypes and associations with ADRD and cerebrovascular biomarkers in the Atherosclerosis Risk in Communities Study
Weigand, Alexandra J. , Erani, Fareshte , Terao, Caitlin M. , Gross, Alden L. , Edmonds, Emily C. , Bangen, Katherine J., Bondi, Mark W. , Windham, B Gwen, Knopman, David S., Gottesman, Rebecca F., Palta, Priya, Walker, Keenan A. , Bangen, Katherine J. , Windham, B. Gwen , Pike, James Russell , Knopman, David S. , Gottesman, Rebecca F. , Thomas, Kelsey R.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S3 | Pages: No page available

10.1002/alz70857_104395 Get It

Abstract Background Even among cognitively unimpaired (CU) older adults, specific patterns of neuropsychological performance impart differential risk for progression to Alzheimer's disease and related dementias (ADRD). Early identification in the prodromal phase may inform early intervention efforts. We used a data‐driven approach to classify neuropsychological phenotypes within CU older adults from the Atherosclerosis Risk in Communities (ARIC) study and tested for differences in ADRD and cerebrovascular outcomes. Method Participants included 4737 CU (via a previously published algorithm plus consensus diagnosis protocol) older adults (mean age=75.1 years, 60.8% female, 23.1% Black) with neuropsychological data from Visit 5 (2011‐2013) of the ARIC study. Latent profile analysis was leveraged to identify unique cognitive phenotypes using 10 demographically adjusted (age, sex/gender, education, race‐center, WRAT Reading) neuropsychological z‐scores. Cognitive phenotypes were then compared on demographics, depressive symptoms, and vascular risk factors (VRFs). In a subset with available neuroimaging and biofluid data ( n range=1102‐1678), white matter hyperintensity (WMH) and bilateral hippocampal (HV) volumes normalized for intracranial volume and plasma biomarkers (i.e., Aβ42/40, ptau181, NfL, and GFAP) were examined by phenotype. Phenotype comparisons adjusted for demographic variables, VRFs, and an indicator of kidney function (i.e., eGFR‐creatinine) for plasma biomarkers. We applied Tukey adjustment for pairwise comparisons. Result A 6‐class solution of cognitive phenotypes emerged as the best fitting model: Average Overall (28%), Low Overall/Very Low Memory (7%), Average Overall/Super Memory (11%), Subtle Low Overall/Low Executive (22%), Subtle Low Executive/High Memory (13%), and Average Overall/Low Memory (19%; Figure 1). Phenotypes differed on education, race, and word reading, despite prior adjustments for these variables when creating the neuropsychological z‐scores (Table 1). Additionally, phenotypes differed on depressive symptoms, VRFs, WMH, HV, Aβ42/40, and ptau181 (all p s < .05). The Subtle Low Overall/Low Executive group had the highest WMH volumes, the Subtle Low Executive/High Memory group had the lowest Aβ42/40, and the Low Overall/Very Low Memory group had the lowest HV and highest levels of plasma ptau181 (Table 2). Conclusion Cognitive heterogeneity is observed even among CU older adults, with lower executive performance associated with cerebrovascular changes and lower memory associated with certain AD‐related changes, possibly indicating risk for cognitive progression through distinct pathways.